nurix
therapeutics
announces
appointment
robert
tjian
chairman
scientific
advisory
board
resignation
board
directors
san
francisco
globe
newswire
nurix
therapeutics
nasdaq
nrix
today
announced
based
desire
lead
nurix
scientific
advisory
board
robert
tjian
resigned
company
board
directors
effective
november
tjian
tij
served
member
board
directors
since
november
tjian
continue
provide
guidance
advice
nurix
new
role
chairman
nurix
scientific
advisory
board
impressed
scientific
achievements
nurix
team
made
basic
translational
science
around
ligases
extremely
challenging
target
class
said
tjian
early
days
first
initiated
discussion
around
formation
nurix
colleagues
micha
rape
john
kuriyan
university
california
berkeley
art
weiss
university
california
san
francisco
much
anticipated
initiation
clinical
trials
first
drug
candidates
nurix
continue
advancing
exciting
scientific
medical
journey
bring
potential
breakthrough
therapies
patients
cancer
deploying
powerful
new
disease
modifying
behalf
entire
nurix
team
would
like
thank
tij
service
past
four
years
continued
commitment
nurix
new
role
chairman
scientific
advisory
board
said
arthur
sands
president
chief
executive
officer
nurix
tij
continue
scientific
north
star
nurix
explore
ligase
drug
discovery
space
bring
targeted
protein
modulation
drugs
clinical
nurix
therapeutics
nurix
therapeutics
biopharmaceutical
company
focused
discovery
development
commercialization
small
molecule
therapies
designed
modulate
cellular
protein
levels
novel
treatment
approach
cancer
immune
disorders
leveraging
nurix
extensive
expertise
ligases
together
proprietary
libraries
nurix
built
deligase
integrated
discovery
platform
identify
advance
novel
drug
candidates
targeting
ligases
broad
class
enzymes
modulate
proteins
within
cell
nurix
drug
discovery
approach
either
harness
inhibit
natural
function
ligases
within
ubiquitin
proteasome
system
selectively
decrease
increase
cellular
protein
levels
nurix
wholly
owned
pipeline
comprises
targeted
protein
degraders
bruton
tyrosine
kinase
signaling
protein
inhibitors
casitas
lymphoma
ligase
regulates
cell
activation
nurix
headquartered
san
francisco
california
information
please
visit
http
forward
looking
statement
statements
made
press
release
relating
future
business
performance
conditions
plans
prospects
trends
strategies
business
matters
including
statements
regarding
plans
respect
finding
highly
qualified
independent
board
member
nurix
board
directors
ability
advance
multiple
wholly
owned
drugs
clinical
development
statements
within
meaning
private
securities
litigation
reform
act
addition
used
press
release
words
may
could
anticipate
believe
estimate
expect
intend
plan
predict
similar
expressions
variants
relate
company
may
identify
statements
statements
neither
historical
facts
assurances
future
performance
instead
based
current
beliefs
expectations
assumptions
regarding
future
company
business
future
plans
strategies
development
plans
preclinical
results
future
conditions
although
believe
expectations
reflected
statements
reasonable
give
assurance
expectations
prove
correct
readers
cautioned
actual
results
levels
activity
performance
events
circumstances
could
differ
materially
expressed
implied
statements
due
variety
factors
including
risks
uncertainties
described
heading
risk
factors
final
prospectus
pursuant
rule
b
filed
securities
exchange
commission
sec
july
quarterly
report
form
filed
sec
october
sec
filings
accordingly
readers
cautioned
place
undue
reliance
statements
except
required
applicable
law
plan
publicly
update
revise
statements
contained
herein
